Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. - Test2 - elhamkhani - TriplyDB

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

http://www.wikidata.org/entity/Q34085036

about

Role of B cells in tolerance induction Using gene therapy to manipulate the immune system in the fight against B-cell leukemias Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies Biology and clinical application of CAR T cells for B cell malignancies Germinal center B cell depletion diminishes CD4+ follicular T helper cells in autoimmune mice BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Murine models of systemic lupus erythematosus Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies CD19 as a molecular target in CNS autoimmunity.Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line.Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.B lymphocytes as therapeutic targets in systemic lupus erythematosus.Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.B lymphocytes differentially influence acute and chronic allograft rejection in mice Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy Targeting B-cells mitigates autoimmune diabetes in NOD mice: what is plan B?Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.A perspective on B-cell-targeting therapy for SLE.B cells as therapeutic targets in SLE.B-lymphocyte effector functions in health and disease.Optimising the delivery of tubulin targeting agents through antibody conjugation.Of mice and men: the need for humanized mouse models to study human IgG activity in vivo.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.B-cell targeted therapeutics in clinical development.Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.Emerging immunological drugs for chronic lymphocytic leukemia.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.

P2860

Q26824451-C3C10599-4E20-4EA2-9DC1-C53443DCD27E Q27011297-D70C311B-BFA4-4F97-B2FC-8FA56A918BFA Q28067334-85567896-A4BD-462F-A1A9-B7BE5A07BB9B Q33907565-E1AEC02A-761E-415F-99DF-2A695D3361C6 Q34015403-E8E0135F-3C98-48F2-8602-6BEA8A2251AF Q34245983-1429B3FD-B1B5-4CF2-A3DF-DC304108C5E2 Q34440110-7AA8168E-C387-4733-AECF-D4EBA1372BAA Q34591019-57F1A421-515C-4D3D-92FD-F69B81FA1964 Q34598149-EFB7A5C7-722C-4362-B00A-1B054152F85D Q34976749-B63F70A7-C1C9-4B72-AC44-0A4FECEAFA44 Q35216023-4B9B0E25-B3B7-4E95-8DB2-A1E8DE6CD456 Q35307091-DA2AEB43-5138-4DBF-AF3B-65F6C814C67E Q35463552-A582E14F-7209-4F72-95C0-CD05FC8B8F9B Q35484992-5CFD99E2-578E-4494-9472-9DE9232BEC07 Q36512143-6CBD59C5-830D-458B-8B78-BB88494E16D9 Q36594664-ECD7B93F-EFC1-4779-B3DE-B4D71695AFD9 Q36653646-3CEC659A-C046-420A-B086-685A6795B43F Q36800456-0F3850A5-B219-41A1-9A7D-C6470C41C341 Q36835221-91395EB8-E793-47EA-A155-EE45DCD75736 Q37072826-9741F102-5970-4550-9DE6-1499519FD2EF Q37117624-9F18B642-2793-4882-8A1F-F5B82E7902E2 Q37236304-7AD63CBC-DEC0-4E97-BCB5-275DB7B8EAB9 Q37388213-68AD02C5-51DA-44CA-8F07-E74120A9E084 Q37577571-6100F0BA-DE9D-4FD8-8A9C-0C29C45C9C72 Q37603296-1A0761C7-17EA-434C-A696-746FAD325E05 Q37815038-63314F80-1B51-4D72-8F4A-558C37174632 Q38024991-2DBDAF31-E2B3-41F9-98B2-9D7AB49F81EA Q38040686-876E9D2F-754C-4303-AD07-E977A09D3BFE Q38071110-76C26748-0E0D-4F06-A57E-67CA2FECF26D Q38097162-9D954AFE-19C0-416B-8964-F07933F553E8 Q38301125-EE3A5171-156B-43C0-95CB-A00335EC5109 Q38543771-5AE831EC-2F04-4907-9045-3FEDF6E67C61 Q38615353-9FB6F1CF-710A-4EB4-A557-E916D79FD58F Q38988648-1362EB83-F45C-4B00-B671-06B6F93A478C Q39004366-D31538A3-FEB8-4304-A81D-D291133B7FAF Q39188128-E74E4F4D-82C5-4E61-A7D8-4CE2A4F13751 Q39477266-B3DADF39-59C6-4BCA-B0C7-ED7594EE5AF1 Q39646209-DDBED57A-5C54-4587-950E-0346F8C7B8B3 Q39650162-8E9D1F87-DFF8-4F18-A663-1A725FE827A9 Q40110864-8778D4A3-381D-45C5-949E-F8422FE3C613

P2860

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

http://www.wikidata.org/entity/Q34085036

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@ast

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@en

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@nl

type

label

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@ast

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@en

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@nl

prefLabel

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@ast

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@en

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@nl

P1433

Q34085036-B9A5B7A1-D697-476F-A849-F9952127093D

P1476

Q34085036-38DE6357-7B9F-4DE0-8C98-C3C0DAC7AC62

P2093

Q34085036-5A5F23FE-C07E-4636-B536-7841D8817166

Q34085036-60823BDE-187F-4385-B580-EFEAD12293C6

Q34085036-CF360FE3-DA3D-4251-9883-635E49605F35

Q34085036-F8D161C6-753E-4905-8957-29CE6EE29838

P2860

Q34085036-066AAB85-A65E-430C-9B6E-DE53170CA8F8

Q34085036-20AF6C94-1759-45AF-9081-1A5FD7B1C01C

Q34085036-25989A12-E88A-45DB-9250-19AD4DCBFDBC

Q34085036-287ECE74-1378-4E08-B810-893163958E18

Q34085036-32F04A9D-4FDA-40E7-BB59-14AC0561E55D

Q34085036-358A56B9-EB05-4854-8909-E110B0765489

Q34085036-36098194-216E-49DB-B3B0-B6DA7B04FBF3

Q34085036-38B49EBB-D560-4B8B-807B-10B978919908

Q34085036-3F3A2DBC-D3CD-428C-B278-02AD243292B4

Q34085036-3FB406FE-5016-4F53-ACA5-6388BCA836C1

P304

Q34085036-A32C1D51-4FD5-497D-ADF9-1805E674C7BD

P31

Q34085036-84B1ED10-9D83-4406-B82C-602E65EB644C

P356

Q34085036-94CBB86D-B617-4D0D-8204-703E6C4E07D5

P407

Q34085036-B20F99F4-0FBE-47E4-9C7D-7A1548308BEE

P433

Q34085036-A8F47791-C749-43DC-A13B-EC69E7F6E249

P478

Q34085036-62173658-B3DA-414E-906A-082222D38B7B

P577

Q34085036-12C53825-94C5-4F54-80D5-42B5204469E2

P5875

Q34085036-7CCBDFDB-8D5A-4F84-8A99-11069B7FCB5A

P698

Q34085036-F50A15E5-90AB-47D0-9784-41B6DE67DE8C

P921

Q34085036-7C16D536-DD49-4430-B54B-A3424EB41299

Q34085036-DE4B92F3-EB7E-48FE-8A12-420C88FA4733

P932

Q34085036-69B269E3-43C0-4928-A20E-57BE43ADA2A0

P356

PNAS.0505539102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Immunotherapy using unconjugat ...... ancies and autoimmune disease.

@en

P2093

Jonathan C Poe

http://www.w3.org/2001/XMLSchema#string

Norihito Yazawa

http://www.w3.org/2001/XMLSchema#string

Thomas F Tedder

http://www.w3.org/2001/XMLSchema#string

Yasuhito Hamaguchi

http://www.w3.org/2001/XMLSchema#string

P2860

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy

Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development

A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

Phenotypic difference of normal plasma cells from mature myeloma cells.

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

Immunotherapy of Non-Hodgkin's lymphomas.

B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications.

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

P304

15178-15183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0505539102

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7549096

http://www.w3.org/2001/XMLSchema#string

P698

16217038

http://www.w3.org/2001/XMLSchema#string

P921

P932

1257712

http://www.w3.org/2001/XMLSchema#string